|
Patent landscape, scope, and claims: |
United States Patent 10,383,876 scope and claims analysis for 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride
Executive summary: U.S. Patent 10,383,876 is a formulation-and-crystallinity oriented estate anchored on the specific chemical entity 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride (formula (II)), with additional claim coverage for (i) crystalline dihydrochloride, (ii) processes for converting compound (I) to the dihydrochloride, (iii) cancer treatment methods including PI3Kα/PI3Kβ mediation, and (iv) pharmaceutical compositions, including compositions with a broadly enumerated set of co-therapies. The strongest infringement hooks are typically salt form (dihydrochloride) + crystallinity and specific HCl/solvent/temperature/pH/seed crystal workflows for producing that salt. Competitive design-around often focuses on switching salt form, avoiding crystalline form, or using materially different preparation parameters that move outside process-claim boundaries.
Note: No patent bibliographic data (publication number, filing date, assignee, specification details, prosecution history, or related family members) was provided with the input. This analysis therefore addresses claim scope and landscape logic strictly from the claim text you supplied, without mapping to a verified claim chart against the full specification or other US family patents.
What does U.S. Patent 10,383,876 claim: dihydrochloride salt entity, crystalline form, and enumerated “solvate/hydrate/tautomer” coverage?
Core entity claim (Claim 1). Claim 1 defines the protected product as the dihydrochloride salt of the named compound (formula (II)), and expressly extends to “a solvate, hydrate or tautomer thereof.”
Scope implication:
- Direct product coverage applies if the active in the drug product is the claimed dihydrochloride (or a covered tautomer/solvate/hydrate).
- The breadth of “solvate, hydrate or tautomer” can matter for commercial substitutes where the supplier uses a different physical form that is still chemically equivalent within those categories.
Secondary entity scope (Claims 17–19).
- Claim 17 is a simplified restatement covering the dihydrochloride salt (and hydrate/tautomer).
- Claim 18 restricts to hydrate.
- Claim 19 is broadest again to the dihydrochloride without explicit solvate class language in that particular dependent claim.
How broad is “crystalline form” coverage (Claim 2) and why it matters for design-around?
Claim 2 adds a key physical-form constraint: the dihydrochloride salt is in crystalline form.
Scope implication:
- If a generic/manufacturer can credibly market or supply a non-crystalline form (amorphous or different solid-state form) while still using dihydrochloride, infringement may still occur under Claim 1, but Claim 2-specific arguments can be used to narrow or defeat claims tied to “crystalline” characterization.
- In practice, physical form often becomes a litigation battleground: XRD patterns, DSC/TGA, microscopy, particle size distribution, and batch-specific solid form.
What is excluded by the claim language?
The claim text does not explicitly cover:
- other hydrochloride stoichiometries (e.g., mono-HCl forms),
- alternative salts (e.g., sulfate, maleate, oxalate) unless they fall under the literal dihydrochloride definition,
- salts not characterized as “dihydrochloride.”
Design-around typically targets this gap.
Which preparation processes for compound (I) → dihydrochloride are protected (Claims 3–6)?
Base process claim (Claim 3). A method comprising adding hydrochloric acid to a compound of formula (I) to form the dihydrochloride salt of formula (II).
Scope implication:
- This is broad in that it only requires HCl addition to convert (I) to the dihydrochloride.
- If “compound (I)” is the immediate precursor used in commercial manufacturing, Claim 3 can create a process infringement risk even where the final isolation differs.
Where does infringement risk tighten (Claims 4–6)?
Dependent Claim 4 adds detailed process steps:
- adding HCl to a suspension until pH 3–4 is reached,
- stirring across a temperature range between freezing point and boiling point,
- optional steps:
- filter and wash,
- adjust filtrate pH to 1.8–2.0 using HCl,
- ethanol addition,
- seed crystal addition,
- filter, wash with water-ethanol, dry.
Claim 5 adds a multi-stage heating regimen with relative timing and temperature relationships:
- start with HCl in acetone/water or ethanol/water,
- first heating at a higher temperature for a shorter time,
- second heating at a lower temperature for a longer time,
- further optional stir at an even lower temperature for a shorter period,
- filtering/washing/drying.
Claim 6 provides a concrete example (harder to design around):
- 36% HCl,
- acetone/water 8:2 (v/v),
- heat 50°C for 0.5 h,
- heat 35°C for 72 h,
- stir at room temperature for 2 h,
- filtration, washing with acetone/water, vacuum oven drying.
How does this affect generic solid-form supply chains?
- Suppliers that run essentially the same conversion, pH setpoints, solvent ratios, and temperature/time holds face higher infringement exposure for process claims.
- If a supplier can show a manufacturing route that:
- avoids the defined pH ranges,
- avoids the ethanol seeding/anti-solvent workflow,
- or uses substantially different solvent systems and thermal profiles,
they may narrow the process-claim footprint, though Claim 3 remains a broad backstop if “hydrochloric acid added to compound (I)” is still met.
What treatment indications are covered: cancer treatment methods and PI3Kα/PI3Kβ mediation (Claims 7, 13, 14, 16)?
General cancer method (Claim 7).
- Treatment of lung cancer, colorectal cancer, or breast cancer.
- Requires administering a therapeutically effective amount of the claimed dihydrochloride salt (or solvate/hydrate/tautomer).
Specific mechanistic mediation (Claim 13).
- Treatment mediated by PI3Kα or PI3Kβ.
- Same administration requirement.
Crystalline-specific treatment (Claim 14).
- Treatment method using the dihydrochloride salt of Claim 2 (i.e., crystalline form).
Mechanistic mediation with crystalline salt (Claim 16).
- Treatment mediated by PI3Kα or PI3Kβ, using the crystalline dihydrochloride salt of Claim 2.
Why PI3Kα/PI3Kβ language matters for enforcement
Mechanism-of-action claim language can:
- align with a specific therapeutic rationale used in clinical development,
- drive argumentation around whether the administered drug is used for that targeted pathway.
Commercial relevance:
- If the marketed product is positioned or used for PI3Kα/β mediated disease states, these claims become easier to assert.
- If usage drifts into other mechanisms/biomarkers outside PI3Kα/β mediation, defense arguments can focus on intended/claimed use.
What pharmaceutical composition claims exist and how do combination-therapy lists expand exposure (Claims 8–12, 9–10)?
Single-agent composition (Claim 8)
A pharmaceutical composition containing:
- the dihydrochloride salt (or solvate/hydrate/tautomer),
- plus one or more pharmaceutically acceptable excipients.
This is a typical, broad product formulation claim. It is generally met if the formulation contains the claimed API salt.
Combination composition (Claim 9)
A composition comprising:
- the dihydrochloride salt as a first agent,
- plus a second pharmaceutical agent selected from an extremely broad list (hundreds of entities including small molecules and biologics).
Claim 10 then specifies that the second agent is from that list. Structurally, that means:
- If an accused product is a combination therapy using one of the listed second agents, the combination formulation claim is triggered.
Specific suspension variant (Claim 11)
Claim 11 covers a method where compound (I) is in suspension.
- This is process-dependent, not composition-dependent.
Non-small cell lung carcinoma limitation (Claim 12 and Claim 15)
- Claim 12: lung cancer is non-small cell lung carcinoma.
- Claim 15 mirrors this for the method tied to crystalline form (Claim 2).
What are the key claim-to-risk pathways for generic entry or ANDA-style challenges?
Because the claims are directly on the chemical salt form (Claim 1/17–19) and crystallinity (Claim 2), and also include methods and compositions, risk typically clusters in three ways:
-
ANDA or 505(b)(2) using the same dihydrochloride solid form
- If the API is dihydrochloride and the dosage form contains it, composition claims (Claims 8/21 and combination claims if applicable) become central.
- Salt and solid-state disclosures in regulatory filings become crucial for infringement.
-
Process litigation against API manufacturers
- Even if the formulation buyer changes downstream formulation steps, process claims (Claims 3–6) can be asserted against upstream API manufacture if the route falls within the claim language.
- The specificity in Claims 4–6 raises the bar for process infringement but also gives clearer “recipe” benchmarks.
-
Labeling/indication mismatch defenses
- Method claims (Claims 7, 13, 14, 16) can be narrowed by dispute over medical use and PI3Kα/β mediation framing.
- However, if the drug is marketed and used for the claimed cancers and pathway rationale, these claims remain high-value.
How strong is the patent estate based on claim architecture (product + solid form + process + method + combinations)?
Even without family verification, the internal architecture is high breadth:
- Product (Claim 1): specific compound as dihydrochloride with solvate/hydrate/tautomer sweep.
- Solid-state refinement (Claim 2): crystalline limitation creates additional layering.
- Process (Claims 3–6): conversion plus increasingly specific workflows including solvent systems, pH, temperature, hold time, filtration/washing, seeding, and explicit example parameters.
- Method-of-use (Claims 7, 13, 14, 16): disease indications plus PI3Kα/β mediation.
- Composition (Claims 8–9): excipient compositions and combination compositions against a broad second-agent list.
Net effect: an alleged infringer must avoid overlap across multiple claim categories to reduce total exposure. Typical strategies are:
- changing from dihydrochloride to another salt form,
- using a solid form that avoids crystalline dihydrochloride status (to reduce Claim 2-dependent method exposure),
- using a materially different manufacturing route to avoid Claims 4–6,
- using a formulation without the claimed API salt (not always feasible),
- avoiding combination therapy selections outside the listed second agents,
- challenging medical-use assumptions for PI3Kα/β mediated treatment.
How does 10,383,876 compare to typical “salt-only” patents, and where is the main leverage?
Compared with “salt-only” patents, this one has:
- method-of-use claims,
- composition claims,
- and explicit manufacturing steps.
Main leverage is twofold:
- Formulation and labeling alignment. If the commercial drug uses the dihydrochloride salt, composition and method claims can be asserted simultaneously.
- Upstream API manufacturing. The HCl conversion workflow and example parameters create identifiable process infringement targets.
What manufacturing/IP barriers does the process claim set create (Claims 3–6)?
Key technical “tripwires”
- Starting material: compound of formula (I).
- Reactant: hydrochloric acid, including concentrated aqueous HCl (Claim 6: 36% HCl).
- Solvent system: acetone/water (8:2 v/v) or ethanol/water (Claims 5–6).
- pH control: pH 3–4, with optional pH adjustment of filtrate to 1.8–2.0 (Claim 4).
- Solid formation controls:
- optional ethanol addition,
- optional seed crystals,
- filtration and wash steps using water-ethanol (Claim 4).
- Thermal profile:
- first higher temperature for shorter time,
- second lower temperature for longer time (Claim 5),
- fixed schedule in example (Claim 6).
Implication for contract manufacturing (CMO/CDMO):
- process deviations that still produce dihydrochloride may still infringe Claim 3; deviations that avoid the specific parameter sets reduce Claim 4–6 exposure but do not eliminate Claim 3 exposure if conversion is still via “adding hydrochloric acid to compound (I).”
Key takeaways
- U.S. Patent 10,383,876 is anchored on a specific API salt identity: the dihydrochloride of a defined imidazoquinazoline-pyrimidine carboxamide scaffold, with added coverage for solvates/hydrates/tautomers.
- Crystallinity is separately claimed (Claim 2), enabling layered enforcement against solid-state variants.
- Process claims are structured for enforceability: Claim 3 captures the generic HCl conversion, while Claims 4–6 add detailed pH/solvent/temperature/seed/ethanol and even a worked example.
- Method-of-use claims expand downstream exposure to lung/colorectal/breast cancers and PI3Kα/PI3Kβ mediated treatment, including crystalline-form-dependent variants.
- Composition claims are broad and combination-ready, with Claim 9/10 capturing co-therapies using an extensive enumerated second-agent list.
- For competitive planning, the practical risk reducers are typically salt-form substitution, avoidance of crystalline dihydrochloride, and material changes to the conversion workflow (solvent, pH windows, seeding/ethanol anti-solvent steps, and thermal schedule).
FAQs
1) Does U.S. Patent 10,383,876 protect only the crystalline dihydrochloride or all dihydrochloride forms?
It protects the dihydrochloride salt broadly (Claim 1/17–19). Crystalline form is specifically added in Claim 2, creating additional layered coverage.
2) Can a different salt form avoid all claims in this patent?
The claims are written around the dihydrochloride (formula (II)). Switching to a non-dihydrochloride salt is the most direct route to avoid the core product claims.
3) Is the manufacturing route protected only when specific temperatures and times are followed?
No. Claim 3 broadly covers adding hydrochloric acid to compound (I) to form the dihydrochloride. Claims 4–6 impose additional parameter-based restrictions.
4) Do the method claims require PI3Kα/PI3Kβ mediation?
Some do. Claims 13 and 16 explicitly require PI3Kα or PI3Kβ mediation, while Claims 7 and 14 cover cancers more generally (with Claim 14 tied to crystalline form).
5) How does the combination composition claim expand exposure for co-administered oncology drugs?
Claim 9/10 allows the second agent to be any selected item from an extensive enumerated list. If an accused combination includes one of those listed agents, composition-claim risk increases.
References (APA)
- United States Patent 10,383,876 (claims as provided in the prompt text).
More… ↓
⤷ Start Trial
|
